Ataibeckley Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Ataibeckley Inc (ATAI) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Ataibeckley Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 4M vs 3,181M combined for its competitors (0.1% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+52.4% annualized vs trailing 12 months), vs holding steady (-1.2%) for its tracked peer group.
- Growth: Ataibeckley Inc generated 137.0% revenue growth year over year in Q2 2026, vs -5.4% for its competitors combined.
- Profitability: Its -1,910.1% net margin compares with -55.7% for the peer group.
- Peer revenue share: Ataibeckley Inc accounted for 0.2% of combined revenue among its tracked peer group, up from 0.1% a year earlier.
- Peer differentiation: Revenue per employee of $0.02M compares with $0.73M for the peer group (0.0x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
ATAI Sales vs. its Competitors, Q2 2026
Ataibeckley Inc reported revenue growth of 137.00 % year on year in Q2 2026, above its competitors' combined revenue change of -5.42 %.
With a net margin of -1,910.09 %, Ataibeckley Inc reported lower profitability than its competitors (-55.73 %).
Ataibeckley Inc generated 0.22 % of the combined sales of its peer group, up from 0.09 % a year earlier.
API endpoints for this dataset
Ataibeckley Inc vs. its Competitors, Q2 2026
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Ataibeckley Inc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Ataibeckley Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Ataibeckley Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Ataibeckley Inc's competitor groups requires a Commercial License.
For context: the Major Pharmaceutical Preparations industry grew revenue 8.9% year over year, combined, vs 137.0% for Ataibeckley Inc. Ataibeckley Inc's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.
Ataibeckley Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Ataibeckley Inc | - | Yes | Yes | No |
| Competitors combined (16) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
ATAI Stock Performance relative to its Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Definium Therapeutics Inc | 282.9% | Outperformed |
| 2 | Alto Neuroscience Inc | 282.9% | Outperformed |
| 3 | Compass Pathways Plc | 282.9% | Outperformed |
| 4 | Indivior Pharmaceuticals Inc | 282.9% | Outperformed |
| 5 | Xenon Pharmaceuticals Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Ataibeckley Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Ataibeckley Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Ataibeckley Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Ataibeckley Inc |
2,651.54 | 4.47 |
 Indivior Pharmaceuticals Inc |
4,426.16 | 1,376.00 |
 Xenon Pharmaceuticals Inc |
3,901.72 | 13.17 |
 Definium Therapeutics Inc |
3,682.48 | - |
 Compass Pathways Plc |
1,399.71 | - |
 Alto Neuroscience Inc |
1,077.18 | - |
| SUBTOTAL | 18,980.34 | 3,415.38 |
Sign in to see all competitors of Ataibeckley Inc .
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Ataibeckley Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Ataibeckley Inc's Competitors Named by the Company
Competitive relationships identified from Ataibeckley Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Incannex Healthcare Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Ataibeckley Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Ataibeckley Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Indivior Pharmaceuticals Inc | Reportable 100.00 % |
| Tripadvisor Inc | Experiences 43.91 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Ataibeckley Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Ataibeckley Inc | 2,652 | 22,144 | -3,308,347 |
| Indivior Pharmaceuticals Inc | 4,426 | 1,376,000 | 451,000 |
| Xenon Pharmaceuticals Inc | 3,902 | 35,597 | -1,105,932 |
| Definium Therapeutics Inc | 3,682 | - | - |
| Compass Pathways Plc | 1,400 | - | -1,707,058 |
| Alto Neuroscience Inc | 1,077 | - | -1,238,794 |
| PEERS TOTAL | 16,329 | 727,428 | -240,544 |
Ataibeckley Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 495 companies in Ataibeckley Inc's industry classification, broader than the peer set above. Market cap in millions of $.Ataibeckley Inc ranks #0 of 495 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 875, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,210,070 | 20.69 % |
| 2 | Johnson and Johnson | 674,004 | 11.53 % |
| 3 | Beone Medicines Ltd | 612,622 | 10.48 % |
| 4 | Abbvie Inc | 515,910 | 8.82 % |
| 5 | Merck and Co Inc | 1,234 | 5.2% |
| 6 | Novartis Ag | 1,234 | 5.2% |
| 7 | Abbott Laboratories | 1,234 | 5.2% |
| 8 | Novo Nordisk A | 1,234 | 5.2% |
| 9 | Pfizer Inc | 1,234 | 5.2% |
| 10 | Astrazeneca Plc | 1,234 | 5.2% |
| 0 | Ataibeckley Inc | 2,652 | 0.00 % |
Market cap and industry share for the rest of Ataibeckley Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-09-11.
Ataibeckley Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Major Pharmaceutical Preparations industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (444 companies). See the full Major Pharmaceutical Preparations industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 0.00 % | 37.89 % (avg) | -37.9 pp |
| Operating Margin | - | industry median | - |
| EBITDA Margin | - | -6.23 % (avg) | - |
| Capital Intensity (Capex / Revenue) | 100.47 % | 7.58 % (avg) | +92.9 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Ataibeckley Inc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (444 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 26.6x | - |
| EV / EBITDA | - | 15.9x | - |
| P/B | 8.0x | 4.3x | +3.8x |
| Return on Equity | -353.07 % | industry aggregate | -369.42 % |
| Return on Invested Capital | -136.84 % | -9.83 % (avg) | -127.01 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Ataibeckley Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2021 | 2022 | 2023 | 2023 | 2024 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue Growth | - | - | - | - | - | - | - |
| Operating Margin | - | - | - | -39,958.92 % | - | - | - |
| Return on Invested Capital | - | -22.66 % | -21.96 % | -24.58 % | -19.71 % | -28.69 % | -164.57 % |
| P/E | - | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Ataibeckley Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 875 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | High (capital intensive) | Capital intensity (capex / revenue) of 100.47 % vs industry average 7.58 % (see Profitability & Cost Structure above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Ataibeckley Inc's dedicated Suppliers and Customers pages, not here.
Ataibeckley Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Latest-quarter revenue run-rate is accelerating (+52.4% annualized vs trailing 12 months).
Weaknesses
- Return on equity 369.4 points below the industry aggregate.
Opportunities
- A meaningful share of competitors (60.00 %) show financial-distress signals, a possible opening to gain share.
Threats
- High capital intensity requires continuous reinvestment just to keep pace with the industry.
Methodology: see Methodology: SWOT Analysis.
Ataibeckley Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Ataibeckley Inc | 3.50 | 9.64 | 0.03 |
| Indivior Pharmaceuticals Inc | 0.23 | 0.74 | - |
| Xenon Pharmaceuticals Inc | 5.87 | 18.75 | - |
| Definium Therapeutics Inc | 3.23 | 5.69 | 0.10 |
| Compass Pathways Plc | 1.36 | 1.52 | 0.40 |
| Alto Neuroscience Inc | 16.39 | 16.63 | 0.11 |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Ataibeckley Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Ataibeckley Inc | Q2 2026 | +137.0 % | - |
| Indivior Pharmaceuticals Inc | Q3 2026 | +13.7 % | +226.2 % |
| Xenon Pharmaceuticals Inc | Q2 2026 | - | - |
| Definium Therapeutics Inc | Q2 2026 | - | - |
| Compass Pathways Plc | Q3 2026 | - | - |
| Alto Neuroscience Inc | Q2 2026 | - | - |
| PEERS TOTAL | +7.5 % | - |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Ataibeckley Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Ataibeckley Inc | Q2 2026 | - | - |
| Indivior Pharmaceuticals Inc | Q3 2026 | -38.6 % | -30.0 % |
| Xenon Pharmaceuticals Inc | Q2 2026 | - | +75.2 % |
| Definium Therapeutics Inc | Q2 2026 | - | - |
| Compass Pathways Plc | Q3 2026 | - | - |
| Alto Neuroscience Inc | Q2 2026 | - | - |
Ataibeckley Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Ataibeckley Inc | - | - | - |
| Indivior Pharmaceuticals Inc | 36.35% | 108.22% | - |
| Xenon Pharmaceuticals Inc | - | - | - |
| Definium Therapeutics Inc | - | - | - |
| Compass Pathways Plc | - | - | - |
| Alto Neuroscience Inc | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Ataibeckley Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Ataibeckley Inc | - | 592.79 |
| Indivior Pharmaceuticals Inc | 8.48 | 3.22 |
| Xenon Pharmaceuticals Inc | - | 296.24 |
| Definium Therapeutics Inc | - | - |
| Compass Pathways Plc | - | - |
| Alto Neuroscience Inc | - | - |
| PEERS AVERAGE | - | 5.56 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.